Document is current

Any future updates will be listed below

Nivolumab bei fortgeschrittenem Nierenzellkarzinom nach Therapie

Crossref DOI link: https://doi.org/10.1007/s00092-018-2081-1

Published Online: 2018-12-01

Published Print: 2018-12

Update policy: https://doi.org/10.1007/springer_crossmark_policy

About CrossMark